In clinical practice, after subtyping, the suitability for immune checkpoint axis-based immunotherapy is usually evaluated by means of the immunohistochemical detection of PD-L1 on tumor cells, which turned out to be a potential predictor of response to inhibitors especially when it is higher than 50% (104). The gene discussed is CD274; the disease is neoplasm.